Humacyte’s chief medical officer acquires $11,625 in common stock

Published 14/04/2025, 14:02
Humacyte’s chief medical officer acquires $11,625 in common stock

In a recent stock transaction, Shamik J. Parikh, the Chief Medical (TASE:BLWV) Officer of Humacyte, Inc. (NASDAQ:HUMA), acquired 7,500 shares of the company’s common stock. The shares were purchased at a price of $1.55 each, totaling $11,625. Following this transaction, Parikh now holds 7,500 shares directly. The purchase comes as HUMA shares have shown strong momentum, posting a 21% gain over the past week, though the stock remains volatile with analyst price targets ranging from $3 to $25. InvestingPro subscribers can access comprehensive insider trading analysis and 10+ additional key insights about HUMA. This acquisition reflects Parikh’s continued investment in the biotechnology firm, known for its work in developing bioengineered human tissues and organs. With a market capitalization of $237 million and a healthy current ratio of 2.4, the company maintains strong liquidity despite its development-stage status. According to InvestingPro’s Fair Value analysis, the stock is currently trading slightly above its intrinsic value.

In other recent news, Humacyte reported a narrower fourth-quarter loss of $0.16 per share, surpassing analyst expectations of a $0.25 per share loss. Despite this, the company generated no revenue in the quarter, mirroring the previous year’s results. This lack of revenue comes after the recent FDA approval of Symvess, a bioengineered blood vessel product for extremity vascular trauma. Humacyte has started its commercial launch, shipping initial units to two Level 1 trauma centers, and 34 hospitals have initiated the approval process to purchase Symvess. Analysts at Benchmark maintain a Buy rating with a $17 target, citing the company’s potential to capture significant market share in surgical procedures requiring vascular grafts. BTIG analyst Ryan Zimmerman also retained a Buy rating but adjusted the price target from $10 to $8, noting the early commercial traction of Humacyte’s products. Humacyte plans to file an IND application in 2025 for coronary artery bypass grafting trials and aims for a supplemental application in 2026 to expand Symvess’ uses for dialysis access. The company ended 2024 with $95.3 million in cash, raising an additional $46.6 million through a public stock offering in March 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.